Epithelioid myofibroblastoma of the breast: A case report and review of the literature

Inaishi, Takahiro; Sakuma, Takahiko; Fukuoka, Tomoki; Ichihara, Shu

doi:10.1016/j.ijscr.2022.107382

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myofibroblastoma is characterized as a solitary, unilateral, painless and mobile tumor, with a firm consistency and slow growth, where it can take months to years to evolve 3,12,13 . There is no preference for race, and it is not associated with genetic predisposition 13 .…”

Section: Discussionmentioning

confidence: 99%

Breast myofibroblastoma in a woman: a case report

Reis,

Leitzke,

Ciaccio

et al. 2023

Mastology

View full text Add to dashboard Cite

Breast myofibroblastoma is a rare benign neoplasm of mesenchymal origin with fibroblastic and myofibroblastic characterizations. Myofibroblastoma has a higher incidence in men between the ages of 50 and 70 years and is less common in women. It is described as a solitary, unilateral, painless and mobile tumor, with a firm consistency and slow growth. Microscopically, it is a non-encapsulated tumor, with lobular growth, consisting of spindle cells organized in short, intersecting fascicles and interrupted by bundles of hyalinized collagen. On ultrasound, it can manifest as a hypoechoic solid mass, well circumscribed, homogeneous and similar to fibroadenoma; whereas, on mammography, a single, well-defined, rounded or discretely lobulated lesion can be observed, without calcifications. We report here the case of a 58-year-old patient with no previous breast complaints, who presented with changes in ultrasound and mammography examinations performed for breast cancer screening. The examinations revealed a suspicious lump in the left breast, classified as BIRADS 4C. Core biopsy described a low-grade spindle cell neoplasm, showing no signs of invasion, with immunohistochemistry results suggesting myofibroblastoma. As treatment, a sectorectomy was performed, and the reevaluated material confirmed the diagnosis of myofibroblastoma due to the positive expression of the markers calponin, CD34, BCL2 and CD99.

show abstract

Section: Discussionmentioning

confidence: 99%

Breast myofibroblastoma in a woman: a case report

Reis,

Leitzke,

Ciaccio

et al. 2023

Mastology

View full text Add to dashboard Cite

show abstract

“…When the cells present atypia, the differential diagnoses are spindle cell metaplastic carcinoma, adenomyoepithelioma, adenosarcoma, osteosarcoma, and myofibroblastic sarcoma. In the absence of atypia, fibromatosis, granulation tissue, pseudoangiomatous stromal hyperplasia (PASH), low-grade adenosquamous carcinoma of the breast, myofibroblastoma, inflammatory myofibroblastic tumor, nodule with spindle cells, lipoma with spindle cells, schwannoma, and neurofibromas should be considered as differentials ( 41 – 43 ).…”

Section: The Pericapsular Spacementioning

confidence: 99%

Breast silicone implants’ pericapsular impairment: current underdiagnosed status

de Faria Castro Fleury

2023

Front. Surg.

View full text Add to dashboard Cite

Many complications related to silicone implants have been reported recently, from clinical symptoms manifestations to association with some specific types of cancer. During the early 2010s, it was believed that implants were biocompatible and inert to the human body and that gel bleeding/leakage events were rare and without repercussions for the human body. However, at the end of 2010s, several studies pointed out that gel bleeding was more frequent than previously believed, and the pathogenic potential of free silicone should not be ignored. The Food and Drug Administration recommends performing magnetic resonance imaging in asymptomatic patients 5–6 years after implant placement. The descriptors in the Breast Imaging and Reporting Data System lexicon seem outdated for classifying the new generations of implants with cohesive gel, which hinders the diagnosis of device complications. In this review, supported by our research data publications related to silicone implants for 6 years on a prospective study protocol, most of them being original articles, we summarized the main complications observed in clinical practice and discuss the impact of these changes on patients’ outcomes focusing on the pericapsular space.

show abstract